Viekira Pak - Hepatitis C Drug Information

Kurongwa

Viekira Pak inonzi co-packed drug combination inoshandiswa kuporesa chirwere chepachirwere chehepatitis C (HCV) . Iko rinosanganisira imwe nhengo yakagadzikana inosanganiswa nemishonga inonzi Technivie (ombitasvir + paritaprevir + ritonavir) yakabatanidzwa pamwe chete nedasabuvir yemishonga.

Mishonga yezvipembenene ombitasvir, paritaprevir uye dasabuvir ndivo vanonyatsoshanda-maitiro anouraya (DAAs) anopindira nekudzoka kwehutachiona.

Chirwere cheRitonavir , chinoshandiswa kakawanda muhutachiona hweHIV , chinosanganiswa kuwedzera mishonga yemishonga yeparitaprevir.

Viekira Pak yakawanda, asi kwete nguva dzose, inobatanidzwa ne ribavirin uye haifaniri kutorwa ne pegylated interferon (peg-interferon).

Viekira Pak yakagamuchirwa musi waDecember 19, 2014 neU.S. Food and Drug Administration (FDA) iyo inoshandiswa kune vanhu vakuru makore gumi nemana kana kupfuura neHCV genotype 1 utachiona, kusanganisira avo vane chirwere chendrhosis (iyo chiropa ichiri kushanda) uye chiropa chinoputika. Kune vanorwara vane chirwere cheprhosis, Dee Pak haina kukurudzirwa.

Viekira Pak inonzi iine mushonga wepureji ye 95% kana kupfuura, ine 2% chete yevarwere vanopedza kurapwa nekuda kwekusagadzikana. Izvo zvakakodzera kushandiswa mune varwere vane HIV / HCV iko-kutapukirwa .

Dosage

Mahwendefa maviri e-co-formulated mapiritsi e ombitasvir + paritaprevir + ritonavir (25mg / 150mg / 100mg) anotora rimwe zuva mangwanani mangwanani nechingwa, pamwe chete tafura imwe yedasabuvir inotorwa kaviri zuva rimwe nerimwe mangwanani uye manheru nechingwa.

Mahwendefa acho anowanikwa zvakanaka mumazuva ose emabhokisi, pamwe nemirayiridzo inowanikwa mubhokisi rimwe nerimwe. Iko-tablet yakagadzirirwa iine pink, firimu-yakavharwa uye yakasimbiswa ne "AV1", nepo tablet yeDasabuvir inonzi beige, yakafukidzwa nefirimu uye yakazara ne "AV2".

Kunyora Zvikurudzira

Viekira Pak inorayirwa pamusoro pechikoro che12 kusvika ku24, maererano nezvirevo zvinotevera:

Nokuda kwechiropa kupfurikidza varwere, Viekira Pak inogona kutorwa ne ribavirin kwemavhiki makumi maviri chete kana hepatic (chiropa) basa yakasikwa uye fibrosis (kupora) ishoma.

Nharaunda Dzakabatana

Maitiro akawandisa anowanzobatanidzwa nekushandiswa kwe Viekira Pak (inoitika kusvika kusvika kune 10% yevarwere) ndeiyi:

Kubatana Kwemishonga

Izvi zvinotevera zvinofanirawo kudziviswa pazvinoshandisa Viekira Pak:

Contraindications nekufungisisa

Kune varwere vane uwandu husinganzwisisiki hwepfungwa, Viekira Pak haisi kukurudzirwa. Viekira Pak inopesana nekushandiswa kune varwere vane urema hwakanyanya.

Viekira Pak inobvumiranawo nekushandiswa mumurwere nemunhu anozivikanwa kuti ane ritonavir (kusanganisira Stevens-Johnson Syndrome, inogona kutyisa upenyu, yose-muviri inoputira kupindura).

Viekira Pak inopesana nemashandisirwo emadzimai ane pamuviri paanoshandiswa ne ribavirin.

Zvinokurudzirwa kuti vakadzi vose vane makore anobereka vana vanofanira kuongororwa mwedzi wega wega nekuda kwepamuviri panguva yekurapa. Inokurudzirwawo kuti murwere nemurume wake mukomana vagoverwa maitiro maviri asingaiti mahomoni ekudzivirira kubata pamuviri, uye kuti anoshandiswa panguva yekurapa uye kwemwedzi mitanhatu gare gare.

Kunobva:

US Food and Drug Administration (FDA). "FDA inobvumira Viekira Pak kuti iite hepatitis C." Silver Spring, Maryland; kudhinda kusunungurwa kwakabudiswa musi waDecember 19, 2014.